Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q3 2025 Earnings Presentation
15 slides from Vitrolife Ab's earnings presentation, Oct 23, 2025
Slide 1: ty REPRODU
ty REPRODU $ y) ee
Slide 2: Third quarter 2025
Third quarter 2025 Bronwyn Brophy O’Connor, CEO Pär Ihrskog, CFO Vitrolife AB (publ) 2025-10-23 2
Slide 3: Q3 2025 Highlights
Q3 /2025 Highlights Q1 /2025 Highlights Growth Americas Strengthened Strong +1%* 5%* +9%* +11%** organizational operating structure cash flow *Organic growth in local currencies excluding discontinued business 3 ** Organic growth in local currencies
Slide 4: Strong growth in Americas
Strong growth in Americas Third quarter 2025 Sales Organic growth in local currencies Gross margin 835 MSEK excluding discontinued business 58.9% (867 MSEK) -4% in SEK +5% (58.6%) impacted by -7% due to currency 3% in local currencies EBITDA Operating cash flow Earnings per share 253 MSEK 255 MSEK 0.
Slide 5: Sales and growth per geographical segment
Sales and growth per geographical segment Americas EMEA APAC Total Organic growth* excluding discontinued +11% +4% +1% +5% business Organic growth* +11% -2% +1% +3% Sales (MSEK) 276 309 250 835 Share of total sales 33% 37% 30% 5 * in local currencies
Slide 6: Market region EMEA
Market region EMEA -6% Total growth, impacted by -4% currency and by -6% discontinued business Net sales, MSEK 383 Organic growth 345 355 334 +4%* 328 326 310 309 -2%** • Sales in Consumables +7% in local currencies (excl. discontinued business) due to share gains in key focus markets. • Sales in Te
Slide 7: Market region Americas
Market region Americas +1% Total growth, impacted by -9% currency Net sales, MSEK 316 311 Organic growth* 287 273 295 276 +11% 270 248 • Strong growth across the entire portfolio in all markets in the region. • Strategic investments in sales and marketing in the US resulted in us delivering our stro
Slide 8: Market region APAC
Market region APAC -6% Total growth, impacted by -8% currency Net sales, MSEK 283 Organic growth* 272 270 266 265 250 250 1% 238 • Strong growth in all markets across the region with the exception of China. • We delivered share gains in disposable devices and our media market position remains strong
Slide 9: Geographical segments
Geographical segments Americas EMEA APAC Total Sales (MSEK) 276 309 250 835 Gross income (MSEK) 149 192 151 492 Gross margin % 54.0% 62.0% 60.4% 58.9% Selling expenses (MSEK) -77 -68 -46 -191 Market contribution (MSEK) 72 123 105 300 Contribution margin % 26.0% 39.9% 42.1% 36.0% Contribution margin
Slide 10: Q3 financial highlights
Q3 financial highlights Net sales of SEK 835 million (867), MSEK -4% in SEK 867 • Organic growth in local currencies +3% 835 -4% • Currency effect -7% • Organic growth in local currencies excluding discontinued business +5% Gross income of SEK 492 million (508) 508 492 • Margin of 58.9% (58.6%) • Fav
Slide 11: Operating expenses
Operating expenses MSEK +4% 348 334 Operating expenses • Selling Expenses: Higher in the US due to investments in sales and marketing, offset by 190 191 lower costs in other regions. • Administrative Expenses: Increase driven by strategic investments in IT and digitalization. • R&D Expenses: Slight
Slide 12: Key financials
Key financials 2025 2024 2025 2024 MSEK* Jul-Sep Jul-Sep Jan-Sep Jan-Sep Sales 835 867 2,548 2,650 Gross Margin, % 58.9 58.6 58.1 58.6 EBITDA 253 289 753 888 EBITDA Margin, % 30.3 33.4 29.5 33.5 Net income 102 116 301 375 EPS, SEK 0.75 0.85 2.23 2.76 Operating cash flow 255 206 475 640 Net Debt / EBIT
Slide 13: Focus for 2025
Focus for 2025 Continue to drive share gain in key markets leveraging the full breadth of the portfolio. Growth Accelerate penetration of our combined EmbryoScope and lab control solutions. Deliver best in class quality and customer service to further differentiate from competitors. Prioriti
Slide 14: Q&A
Q&A Contact: investors@vitrolife.com
Slide 15: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there